Table 1.
Model parameters for spectrum input and cost-effectiveness analysis of HIV and syphilis testing scale up among key populations in Viet Nam
| Model parameter | Value |
| HIV Prevalence | |
| MSM (incl. TGW)* | 10.8% |
| PWID** | 12.7% |
| FSW* | 3.6% |
| Syphilis prevalence12 | |
| MSM (incl. TGW) | 6.7% |
| PWID | 0.3% |
| FSW | 2.1% |
| Baseline syphilis test acceptance | |
| MSM (incl. TGW)16 49 50 | 27% |
| PWID17 | 16% |
| FSW18 51 | 35% |
| Syphilis DALYs averted52 | |
| DALYs averted per syphilis case treated | 0.04 |
| ART | |
| 2019 coverage†† | 70% |
| Annual scale-up† | 4.8% |
| Transmission reduction efficacy‡ | 70% |
| Mortality reduction efficacy‡ | 80% |
| Other prevention | |
| Condom use† | 50% |
| Condom efficacy‡ | 80% |
| PrEP coverage (MSM incl. TGW)† | 5% |
| PrEP efficacy‡ | 90% |
| PrEP adherence‡ | 80% |
| Costs†* | |
| HIV lay test§ | $4.50 |
| Syphilis RPR§ | $6.28 |
| Syphilis TPHA§ | $10.26 |
| HIV/syphilis dual test§ | $6.50 |
| ART¶ | $285 |
| Syphilis treatment | $6.50 |
| Time horizon | 2020–2035 |
| Discount rate | 3% |
*2018 Viet Nam HIV Sentinel Surveillance.
†Assumed.
‡Spectrum model prior.
§Testing costs include labour, incentives, travel costs and test kits. Primary cost driver between tests is the cost of the test kit.
¶ART cost includes labour, laboratory monitoring costs, antiretroviral drugs (ARVs) and other recurring costs.
**2019 Viet Nam HIV Sentinel Surveillance.
††Based on information from in-country source.
ART, antiretroviral therapy; DALY, disability-adjusted life-year; FSW, female sex workers; MSM, men who have sex with men; PrEP, pre-exposure prophylaxis; PWID, people who inject drugs; RPR, rapid plasma reagin; TGW, transgender women; TPHA, treponema pallidum haemagglutination assay.